Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.
OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.
In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.
Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.
AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.
Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.
Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.